Novavax Plan Outlines Expansion of Gaithersburg Corporate Campus Company says it could add 400 jobs within four years The biotechnology company Novavax, which is at the forefront of the COVID-19 [….]
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.
BioBuzz is proud to feature the all-female teams at Aurinia Pharmaceuticals and U.S. Pharmacopeia (USP) for Women’s History Month 2021.
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials – 100% protection against severe disease – Final analysis in U.K. trial confirms 96% efficacy [….]
The BioHealth Capital Region (BHCR) had a remarkable 2020, and there is palpable momentum and excitement in the air as we approach the end of Q1 2021. How will the pandemic impact the region’s push to be “Top 3 by 2023?” Where will this significant momentum lead? These questions are yet to be answered.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., February 4, 2021 [….]
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with [….]
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, [….]
